[
    {
        "contents": "data\\TR\\20161221-222133.news",
        "description": null,
        "guid": "yahoo_finance/3033774268",
        "link": "http://us.rd.yahoo.com/finance/external/xcapitalcube/rss/SIG=145u9bj26/*http://www.capitalcube.com/blog/index.php/trillium-therapeutics-inc-tr-ca-earnings-analysis-q3-2016-by-the-numbers-december-5-2016/",
        "pubDate": "Mon, 05 Dec 2016 16:40:21 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics, Inc. :TR-CA: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016"
    },
    {
        "contents": "data\\TR\\20161221-222135.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. , a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today presented data from an ongoing study with its lead drug candidate, ...",
        "guid": "yahoo_finance/957973941",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-presents-initial-data-ongoing-170000629.html",
        "pubDate": "Sat, 03 Dec 2016 17:00:00 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at the American Society of Hematology Annual Meeting"
    },
    {
        "contents": "data\\TR\\20161221-222137.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it will host a conference call and webcast at 8:30 ...",
        "guid": "yahoo_finance/3181295095",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-announces-conference-call-120000220.html",
        "pubDate": "Tue, 29 Nov 2016 12:00:00 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics Announces Conference Call and Webcast on December 5th to Discuss TTI-621 Data Presented at ASH"
    },
    {
        "contents": "data\\TR\\20161221-222139.news",
        "description": null,
        "guid": "yahoo_finance/3168224048",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://sg.finance.yahoo.com/news/trillium-reports-3q-loss-140733794.html",
        "pubDate": "Thu, 10 Nov 2016 14:07:33 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium reports 3Q loss"
    },
    {
        "contents": "data\\TR\\20161221-222141.news",
        "description": null,
        "guid": "yahoo_finance/686673768",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-reports-3q-loss-140733705.html",
        "pubDate": "Thu, 10 Nov 2016 14:07:33 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium reports 3Q loss"
    },
    {
        "contents": "data\\TR\\20161221-222143.news",
        "description": "[at noodls] - Additional clinical data from TTI-621 Phase 1a trial to be presented at 2016 American Society of Hematology (ASH) annual meeting in December Phase 1 trial with TTI-621 in solid tumors open for enrollment ...",
        "guid": "yahoo_finance/2297516602",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128l9mrkd/*http://www.publicnow.com/view/635DD8C8783D892E9BA0FC1B12F829400CAFBB3E",
        "pubDate": "Thu, 10 Nov 2016 12:11:07 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Reports Third Quarter 2016 Financial Results and Provides Corporate Update"
    },
    {
        "contents": "data\\TR\\20161221-222143.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. (TRIL)(TR.TO), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the three and nine months ended September 30, 2016. \"We established a well-tolerated dose of TTI-621 in first part of the Phase 1a/1b trial in relapsed or refractory hematologic malignancies and look forward to presenting data at next month's ASH meeting. In November, the Phase 1b dose expansion cohorts in the TTI-621 trial in patients with advanced hematologic malignancies were opened for enrollment.",
        "guid": "yahoo_finance/2833267355",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-reports-third-quarter-2016-120000787.html",
        "pubDate": "Thu, 10 Nov 2016 12:00:00 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Reports Third Quarter 2016 Financial Results and Provides Corporate Update"
    },
    {
        "contents": "data\\TR\\20161221-222144.news",
        "description": "[at noodls] - TORONTO, Nov. 3, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is scheduled to present ...",
        "guid": "yahoo_finance/2405892859",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128s4g59i/*http://www.publicnow.com/view/600F367593083605BAA7341EA88BC10CE5404AF0",
        "pubDate": "Thu, 03 Nov 2016 11:07:26 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics Announces Investor and Scientific Presentation Schedule for Remainder of 2016"
    },
    {
        "contents": "data\\TR\\20161221-222144.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is scheduled to present an update on the company's programs and progress ...",
        "guid": "yahoo_finance/3480191075",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-announces-investor-scientific-110000505.html",
        "pubDate": "Thu, 03 Nov 2016 11:00:00 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics Announces Investor and Scientific Presentation Schedule for Remainder of 2016"
    },
    {
        "contents": "data\\TR\\20161221-222146.news",
        "description": "[at noodls] - TORONTO, Nov. 2, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, has advanced its novel ...",
        "guid": "yahoo_finance/3848807346",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128gj51k2/*http://www.publicnow.com/view/A170FD1E9DB7080A80836BDB50FB07DC575F5F3E",
        "pubDate": "Wed, 02 Nov 2016 11:10:10 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics Advances TTI-621 Into Phase 1B Cohort Expansion Enrollment"
    },
    {
        "contents": "data\\TR\\20161221-222146.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. , a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, has advanced its novel investigational drug TTI-621, a SIRPa-IgG1 Fc fusion ...",
        "guid": "yahoo_finance/1332910865",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-advances-tti-621-110000882.html",
        "pubDate": "Wed, 02 Nov 2016 11:00:00 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics Advances TTI-621 Into Phase 1b Cohort Expansion Enrollment"
    },
    {
        "contents": "data\\TR\\20161221-222148.news",
        "description": null,
        "guid": "yahoo_finance/1409634109",
        "link": "http://us.rd.yahoo.com/finance/external/xcapitalcube/rss/SIG=147ose7u7/*http://www.capitalcube.com/blog/index.php/trillium-therapeutics-inc-tr-ca-earnings-analysis-q2-2016-by-the-numbers-september-16-2016/",
        "pubDate": "Fri, 16 Sep 2016 16:41:44 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics, Inc. :TR-CA: Earnings Analysis: Q2, 2016 By the Numbers : September 16, 2016"
    },
    {
        "contents": "data\\TR\\20161221-222153.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company has established an industry postdoctoral ...",
        "guid": "yahoo_finance/3273511851",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-introduces-industry-postdoctoral-110000999.html",
        "pubDate": "Wed, 31 Aug 2016 11:00:00 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics Introduces Industry Postdoctoral Fellowship Program"
    },
    {
        "contents": "data\\TR\\20161221-222154.news",
        "description": "[at noodls] - Toronto, Ontario, August 31, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today ...",
        "guid": "yahoo_finance/4247710028",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=1283bon7s/*http://www.publicnow.com/view/0CDDBDB90A821A609779D3C871295010A163F26A",
        "pubDate": "Tue, 30 Aug 2016 19:53:02 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics Introduces Industry Postdoctoral Fellowship Program"
    },
    {
        "contents": "data\\TR\\20161221-222155.news",
        "description": "[at noodls] - Toronto, Ontario, August 23, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today ...",
        "guid": "yahoo_finance/2534487299",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128krum2b/*http://www.publicnow.com/view/CE83C1926A8073643E0B662295F811F5C5EF48F1",
        "pubDate": "Tue, 23 Aug 2016 11:18:06 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics to Present at Investor and Scientific Conferences in September"
    },
    {
        "contents": "data\\TR\\20161221-222155.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on ...",
        "guid": "yahoo_finance/2195596355",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-present-investor-scientific-110000254.html",
        "pubDate": "Tue, 23 Aug 2016 11:00:00 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics to Present at Investor and Scientific Conferences in September"
    },
    {
        "contents": "data\\TR\\20161221-222156.news",
        "description": "[at noodls] - Toronto, Ontario, August 17, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today ...",
        "guid": "yahoo_finance/3211463728",
        "link": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=1283rpj20/*http://www.publicnow.com/view/578E365BE972DF950BC4353E7BBB210A4BB433E0",
        "pubDate": "Wed, 17 Aug 2016 11:11:05 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics Receives FDA Clearance to Proceed with TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides"
    },
    {
        "contents": "data\\TR\\20161221-222157.news",
        "description": "[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the US Food and Drug Administration has provided ...",
        "guid": "yahoo_finance/1148880496",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-receives-fda-clearance-110000353.html",
        "pubDate": "Wed, 17 Aug 2016 11:00:00 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides"
    },
    {
        "contents": "data\\TR\\20161221-222158.news",
        "description": null,
        "guid": "yahoo_finance/2964886933",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://sg.finance.yahoo.com/news/trillium-reports-2q-loss-115033085.html",
        "pubDate": "Fri, 12 Aug 2016 11:50:33 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium reports 2Q loss"
    },
    {
        "contents": "data\\TR\\20161221-222201.news",
        "description": null,
        "guid": "yahoo_finance/1152651927",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-reports-2q-loss-115033896.html",
        "pubDate": "Fri, 12 Aug 2016 11:50:33 GMT",
        "source": "data\\TR\\20161221.rss",
        "title": "Trillium reports 2Q loss"
    }
]